靶向治疗：索拉非尼在肝功能受损的肝癌患者中的作用。 - Suppr

Suppr

超能文献

Targeted therapies: Role of sorafenib in HCC patients with compromised liver function.

作者信息

Di Maio Massimo, Daniele Bruno, Perrone Francesco

机构信息

Clinical Trials Unit, National Cancer Institute-G.Pascale Foundation, Napoli, Italy.

出版信息

Nat Rev Clin Oncol. 2009 Sep;6(9):505-6. doi: 10.1038/nrclinonc.2009.114.

DOI:10.1038/nrclinonc.2009.114

PMID:19707242

Abstract

摘要

相似文献

Targeted therapies: Role of sorafenib in HCC patients with compromised liver function.

Nat Rev Clin Oncol. 2009 Sep;6(9):505-6. doi: 10.1038/nrclinonc.2009.114.

Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy?

J Gastrointest Cancer. 2010 Dec;41(4):217-20. doi: 10.1007/s12029-010-9163-y.

Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma.

Dig Liver Dis. 2012 May;44(5):361-2. doi: 10.1016/j.dld.2012.02.014. Epub 2012 Mar 14.

Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma?

J Gastroenterol Hepatol. 2011 Nov;26(11):1585-6. doi: 10.1111/j.1440-1746.2011.06901.x.

Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.

Clin Drug Investig. 2012 Aug 8;32 Suppl 2:1-2. doi: 10.1007/BF03265491.

Sorafenib in hepatocellular carcinoma.

Br J Hosp Med (Lond). 2010 Aug;71(8):451-6. doi: 10.12968/hmed.2010.71.8.77669.

Sorafenib and radiation therapy for the treatment of advanced hepatocellular carcinoma.

J Gastrointest Cancer. 2012 Jun;43(2):344-8. doi: 10.1007/s12029-010-9194-4.

Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system.

Clin Drug Investig. 2012 Aug 8;32 Suppl 2:37-51. doi: 10.1007/BF03265495.

Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.

HPB (Oxford). 2010 Jun;12(5):321-2. doi: 10.1111/j.1477-2574.2010.00186.x.

What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.

Oncology (Williston Park). 2011 Mar;25(3):283-91, 295.

引用本文的文献

Serum apolipoprotein H determines ferroptosis resistance by modulating cellular lipid composition.

Cell Death Dis. 2024 Oct 1;15(10):718. doi: 10.1038/s41419-024-07099-2.

Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts.

PLoS One. 2022 Mar 24;17(3):e0265668. doi: 10.1371/journal.pone.0265668. eCollection 2022.

Safety and Efficacy of Physical Thermal Ablation Combined Sorafenib for Hepatocellular Carcinoma: A Meta-analysis.

J Clin Transl Hepatol. 2021 Apr 28;9(2):149-159. doi: 10.14218/JCTH.2020.00125. Epub 2021 Mar 8.

Safety and Efﬁcacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis.

Clin Exp Gastroenterol. 2020 Oct 1;13:385-396. doi: 10.2147/CEG.S256691. eCollection 2020.

Comparative analysis of tumor-associated vascular changes following TACE alone or in combination with sorafenib treatment in HCC: A retrospective study.

Oncol Lett. 2018 Sep;16(3):3690-3698. doi: 10.3892/ol.2018.9055. Epub 2018 Jul 2.

Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.

Oncol Rep. 2017 Aug;38(2):899-907. doi: 10.3892/or.2017.5722. Epub 2017 Jun 14.

Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.

Mol Cancer Ther. 2016 Nov;15(11):2553-2562. doi: 10.1158/1535-7163.MCT-15-0976. Epub 2016 Aug 5.

Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis.

Med Sci Monit. 2015 Oct 18;21:3144-51. doi: 10.12659/msm.894617.

SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.

Neoplasia. 2014 Jul;16(7):595-605. doi: 10.1016/j.neo.2014.06.005. Epub 2014 Jul 18.

Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience.

Med Oncol. 2014 May;31(5):948. doi: 10.1007/s12032-014-0948-x. Epub 2014 Apr 17.

本文引用的文献

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.

J Clin Oncol. 2009 Apr 10;27(11):1800-5. doi: 10.1200/JCO.2008.20.0931. Epub 2009 Mar 2.

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

J Clin Gastroenterol. 2009 May-Jun;43(5):489-95. doi: 10.1097/MCG.0b013e31818ddfc6.

Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.

Oncologist. 2009 Jan;14(1):67-9. doi: 10.1634/theoncologist.2008-0281. Epub 2009 Jan 15.

Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.

Oncologist. 2009 Jan;14(1):70-6. doi: 10.1634/theoncologist.2008-0191. Epub 2009 Jan 14.

Sorafenib for the treatment of unresectable hepatocellular carcinoma.

Oncologist. 2009 Jan;14(1):95-100. doi: 10.1634/theoncologist.2008-0185. Epub 2009 Jan 14.

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.

Sorafenib in advanced hepatocellular carcinoma.

N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.

Design and endpoints of clinical trials in hepatocellular carcinoma.

J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13.

Transection of the oesophagus for bleeding oesophageal varices.

Br J Surg. 1973 Aug;60(8):646-9. doi: 10.1002/bjs.1800600817.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验